Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21588244 | 0.96 | GAA (0.55) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL29129581 | 0.95 | GAA (0.58) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL5281585 | 0.95 | GAA (0.58) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL29129524 | 0.95 | GAA (0.58) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL29129571 | 0.95 | GAA (0.58) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL3916388 | 0.95 | GAA (0.58) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL6027856 | 0.92 | GAA (0.50) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL15026735 | 0.87 | BTK (0.49) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL15026749 | 0.86 | GAA (0.45) | BTKGAASMN1; SMN2HSD17B10KMT2A | |
| SCHEMBL440267 | 0.84 | GAA (0.44) | BTKGAASMN1; SMN2HSD17B10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234226-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2025-02-25 | — | — | US | disclosed |
| EP-3802501-B1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPHARMA LTD (KY) | 2024-02-28 | — | — | EP | disclosed |
| EP-3802501-B1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPHARMA LTD (KY) | 2024-02-28 | — | — | EP | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-09-28 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XWPharma Ltd. (KY) | 2023-09-26 | — | — | US | disclosed |
| CN-115089586-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-112566902-B | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-06-01 | — | — | US | disclosed |
| CN-112566902-A | Compounds as nuclear transport modulators and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-03-25 | — | — | US | disclosed |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-03-25 | — | — | US | disclosed |
| WO-2019233447-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XW LABORATORIES, INC. (CN) | 2019-12-12 | — | — | WO | disclosed |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020395-B2 | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | BTK 3473/4885GAA 4638/4885SMN1; SMN2 4642/4885 |
| US-12234226-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | BTK 4822/4885GAA 1067/4885SMN1; SMN2 865/4885 |
| US-11767313-B2 | Compounds as nuclear transport modulators and uses thereof | XPOT, XPO1, XPO5 | BTK 4822/4885GAA 1067/4885SMN1; SMN2 865/4885 |
| US-20230303530-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | BTK 4822/4885GAA 1067/4885SMN1; SMN2 865/4885 |
| US-20210087177-A1 | COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPOT, XPO1, XPO5 | BTK 4822/4885GAA 1067/4885SMN1; SMN2 865/4885 |
| US-20190290648-A1 | CYCLOALKYL SUBSTITUTED TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | BTK 3473/4885GAA 4638/4885SMN1; SMN2 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.